Stoke Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Stoke Therapeutics, Inc. carries a market capitalization of 1.60B, placing it among publicly traded companies globally.
| Market Cap | 1.60B |
| Enterprise Value | N/A |
Share Statistics
Stoke Therapeutics, Inc. currently has 62.40M shares outstanding.
| Shares Outstanding | 62.40M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Stoke Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 33.58. The price-to-sales ratio is 74.20, and the price-to-book ratio stands at 5.91.
| PE Ratio | 33.58 |
| PS Ratio | 74.20 |
| PB Ratio | 5.91 |
| P/TBV Ratio | 5.91 |
| P/FCF Ratio | -11.68 |
| P/OCF Ratio | -11.50 |
Financial Position
Stoke Therapeutics, Inc. maintains a current ratio of 7.69, meaning it holds 7.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.69 |
| Quick Ratio | 7.19 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -61.10 |
| Return on Assets (ROA) | -53.41 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -1.28M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Stoke Therapeutics, Inc.'s stock has declined approximately -28.36941% over the past 52 weeks. The 50-day moving average sits at 28.54, while the 200-day moving average is 31.21.
| Beta (5Y) | N/A |
| 52-Week Price Change | -28.36941% |
| 50-Day Moving Average | 28.54 |
| 200-Day Moving Average | 31.21 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Stoke Therapeutics, Inc. generated 27.59M in revenue and converted that into -207.90M in net income, yielding earnings per share of -3.32. EBITDA reached -221.63M, while operating income came in at -223.38M.
| Revenue | 27.59M |
| Gross Profit | N/A |
| Operating Income | -223.38M |
| Pretax Income | -209.18M |
| Net Income | -207.90M |
| EBITDA | -221.63M |
| EBIT | -223.38M |
| Earnings Per Share (EPS) | -3.32 |
Balance Sheet
Total book value stands at 345.55M, with working capital of 280.61M providing operational flexibility.
| Cash & Cash Equivalents | 292.82M |
| Total Debt | N/A |
| Net Debt | -110.00M |
| Equity (Book Value) | 345.55M |
| Book Value Per Share | 5.54 |
| Working Capital | 280.61M |
Cash Flow
Stoke Therapeutics, Inc. produced -177.99M in operating cash flow over the past twelve months. After subtracting -2.69M in capital expenditures, free cash flow totaled -180.68M - equivalent to -2.89 per share.
| Operating Cash Flow | -177.99M |
| Capital Expenditures | -2.69M |
| Free Cash Flow | -180.68M |
| FCF Per Share | -2.89 |
Margins
Stoke Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -809.69 and net profit margin of -753.60 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -809.69 |
| Pretax Margin | -758.23 |
| Profit Margin | -753.60 |
| EBITDA Margin | -803.37 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -8.90 |
| FCF Yield | -8.56 |
Scores
Stoke Therapeutics, Inc. posts an Altman Z-Score of 22.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 22.19 |